T he secretory phospholipase A 2 (sPLA 2 ) family hydrolyzes glycerophospholipids at the sn-2 position to generate lysophospholipids and free fatty acids. Ten members have been described in mammals. These enzymes must be clearly distinguished from the intracellular phospholipase A 2 s that are involved in intracellular signaling. They are also distinct from lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), which has been shown to be bound predominantly to LDL particles in human plasma, and hydrolyzes oxidized LDL to generate lysophosphatidylcholine and oxidized nonesterified fatty acids. 1 Group IIa sPLA 2 , which was originally isolated from rheumatoid arthritis fluids, is considered to be the prototypic inflammatory sPLA 2 . Its expression is markedly elevated in many cell types in response to proinflammatory stimuli. The concentration of Group IIa sPLA 2 in sera or exudating fluids correlates well with the severity of inflammatory disease. In humans, Group IIa and Group V sPLA 2 are tightly linked on chromosome 1 and their gene regulation and functions have largely been viewed as overlapping. Indeed, cross-reactivity of antibodies and molecular probes for these related enzymes has led to confusion in older literature. The study by Rosengren et al, reported in this issue, provides new insights into the expression and functional activity of Group IIa and Group V sPLA 2 in the context of atherosclerosis. 2 
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A role for sPLA 2 s in atherogenic processes has been suggested by epidemiological studies showing that in humans, serum concentrations of Group IIa sPLA 2 is an independent risk factor for coronary artery disease and a predictor of cardiovascular events. 3, 4 However, because it is well recognized that this enzyme is highly induced in a number of tissues during inflammation, there was uncertainty as to whether this association merely reflected the fact that Group IIa sPLA 2 is a marker for inflammation. Whether Group V sPLA 2 is an acute phase protein that appears in the plasma during inflammation is less certain. New evidence provided by Rosengren et al 2 that Group V sPLA 2 , unlike Group IIa, is not induced in mice treated with lipopolysaccharide (LPS) is consistent with other findings in humans indicating that sera from patients experiencing inflammatory diseases contain Group IIa sPLA 2 , and not Group V sPLA 2 . 5 It seems reasonable to propose that the major contribution of Group V sPLA 2 to the pathogenesis of atherosclerosis would be effected at the level of the vessel wall.
The finding in 1999 that transgenic expression of human Group IIa sPLA 2 in C57BL/6 mice (this strain lacks the expression of endogenous Group IIa sPLA 2 ) leads to spontaneous atherosclerotic lipid deposition even in the absence of dyslipidemia provided compelling evidence that sPLA 2 may play a causal role in atherosclerosis and is not just a marker for the disease. 6 Subsequent studies showing that macrophage expression of human Group IIa sPLA 2 accelerates atherosclerosis in mice highlighted the possibility that the mechanism of the pathogenic effect of sPLA 2 may be located within the vessel wall, independent of systemic effects. 7 Recent studies, including the accompanying article, 2 establish that at least 3 different members of the sPLA 2 family are present in atherosclerotic lesions (Group IIA, Group V, and Group X sPLA 2 ). This suggests the intriguing possibility that multiple enzymes may contribute locally to atherosclerotic processes, and raises the question: Are these enzymes redundant, or do they provide separate functions?
Rosengren et al 2 report that Group V sPLA 2 , but not Group IIa sPLA 2 , hydrolyzes lipoprotein phospholipids in the presence of complete serum. This is consistent with earlier reports indicating that Group V sPLA 2 is more potent in hydrolyzing HDL and LDL compared with Group IIa sPLA 2 . 8, 9 However, despite this convincing in vitro data, the large body of evidence pointing to the importance of Group IIa sPLA 2 in modulating HDL metabolism in vivo should not be ignored. When induced during inflammation, this isozyme associates selectively with HDL and appears to modify the HDL particle. Transgenic mice expressing human Group IIa sPLA 2 have lower plasma concentrations of HDL cholesterol and apoA-I compared with normal mice, and HDL particles in the transgenic mice are markedly smaller and relatively phospholipid depleted compared with normal mouse HDL. 6 Furthermore, HDL from transgenic mice is markedly depleted of paraoxonase activity, an enzyme that is believed to be partly responsible for the protective effects of HDL. 6 The decreased plasma HDL levels in Group IIa sPLA 2 transgenic mice appears to be attributed to enhanced HDL catabolism, a phenomenon which is associated with altered tissue uptake of HDL cholesteryl ester and apoA-I. 10, 11 The relevance of these findings in mice to the human condition seems likely, given the markedly reduced HDL levels in rheumatoid arthritis patients, who have increased plasma Group IIa sPLA 2 and accelerated atherosclerosis.
The significance of Group IIa or Group V sPLA 2 hydrolysis on HDL function in the vessel wall is not clear. On the one hand, hydrolysis by sPLA 2 results in a significant decrease in the capacity of HDL to mediate cellular cholesterol efflux from lipid-loaded macrophages. 9 On the other hand, phospholipid depletion by sPLA 2 has a major impact on HDL remodeling by cholesteryl ester transfer protein (CETP). Compared with remodeling by CETP alone, the combined action of sPLA 2 and CETP enhances the generation of pre-beta migrating, lipid-free/ lipid-poor apoA-I, 12 the preferred substrate for ABCA1-dependent cellular cholesterol efflux. This effect on HDL remodeling is intriguing and raises the possibility that during inflammation, sPLA 2 s may fundamentally alter the ratio between HDL-bound and free apolipoproteins. If this is the case, this scenario can be envisaged to promote both the effluxing capacity and catabolism of HDL.
Accumulating evidence suggests that LDLs hydrolyzed by sPLA 2 acquire proatherogenic properties. Rosengren et al demonstrate for the first time that Group V sPLA 2 activity toward LDL is significantly enhanced in the presence of proteoglycans. 2 Thus, extracellular matrix (ECM) proteoglycans play an active role in lipid accumulation in the vessel wall by not only mediating the retention of LDL particles, but by also modulating the activity of LDL hydrolytic enzymes. Interestingly, recent data suggests that hydrolysis by Group V sPLA 2 promotes the interaction of LDL particles with cellsurface proteoglycans, and thereby promotes their uptake by macrophages. 13 Thus, in regions where LDL is being accumulated, the colocalization of LDL, proteoglycans, and Group V sPLA 2 leads to a self-perpetuating cascade of events that culminates in atherosclerosis.
Are Group IIa and Group V sPLA 2 redundant with respect to atherogenesis? In vivo data suggests that the acute phase Group IIa sPLA 2 plays the predominant, if not exclusive, role in modulating systemic lipoprotein metabolism, despite its relatively weak ability to hydrolyze LDL and HDL in vitro. Whereas Group IIa sPLA 2 is induced by proinflammatory cytokines, novel data presented by Rosengren et al suggest that Group V sPLA 2 may be upregulated by bioactive lipids. 2 The presence of Group V sPLA 2 in lipid-rich regions of human and mouse atherosclerotic lesions, its potent activity toward LDL, and its activation by proteoglycans, all point to this enzyme as an important player in the generation of proatherogenic LDL. Clearly, the enzymes investigated by Rosengren et al profoundly influence lipoprotein structure. The functional and pathogenetic implications, particularly during inflammation, merits further study.
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